Drug
Bnt324
Bnt324: highest development phase Phase 3, developed by BioNTech. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- BioNTech
Trials
| Drug | Phase | Indication |
|---|---|---|
| BNT324 NCT07365995 | Phase 3 | Metastatic Castration-resistant Prostate Cancer |
| BNT324 NCT06892548 | Phase 1/2 | Advanced Lung Cancer |
Latest
No recent events.
Follow Bnt324 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.